2023年5月18日

Cyted增加£13.4 m進一步癌症診斷提供5月18日2023年早期癌症診斷公司Cyted宣布融資輪£1340萬共同整編和晨邊高地公司從私人投資者參與。投資包括£340萬non-dilutive格蘭特NHS癌症計劃,在春天早些時候宣布。×投資概念的融資將用於現有的市場規模,以及進入美國市場,進一步發展Cyted跨胃腸道癌症和疾病的研究和發展項目。它將支持擴大Cyted的工作提供為食道癌早期檢測測試NHS病人在初級和社區保健設置。NHS癌症計劃格蘭特,提供SBRI醫療的支持,將使用Cyted提供進一步測試社區在蘭開夏郡和南坎布裏亞郡,英格蘭東部和威塞克斯地區癌症聯盟。它遵循£500000撥款SBRI醫療2022年春天一個單獨的項目提供社區測試在英格蘭的西北部。Cyted診斷平台結合了一個非侵入性的測試和數據驅動的生物標誌物早期診斷和危險分層的癌症和炎症性疾病。首次應用在食道癌。成立於三年前,該公司已交付超過15000的測試診斷和監測患者從巴雷特食管,食道癌的前體,在超過80個網站在英國。由一個團隊包括麗貝卡·菲茨傑拉德教授OBE和Marcel Gehrung博士,來自劍橋大學Cyted帶來突破性的科學工業是一個典型的例子。 The test has also been undergoing rollout in community settings since August 2022, including primary care sites. Oesophageal cancer is a global public health priority, with late diagnoses and long waiting times for endoscopies leading to poor survival rates. Earlier diagnosis and better monitoring of Barrett’s oesophagus patients, who are at higher risk of developing oesophageal cancer, can help ensure that cancer is caught early and treated. By identifying cancer in its earliest stages, Cyted's technology helps to reduce the number of unnecessary endoscopies has the potential to significantly improve patient outcomes and save lives - and is already doing so. Marcel Gehrung, Cyted’s CEO, said: "We are thrilled to have the support of existing and new investors as we work to bring our diagnostic products to more markets. This funding demonstrates a vote of confidence in our technology. Early-stage cancer is a major global health issue, and we believe that our technology has the potential to make a real difference in the lives of even more patients and their families." The company plans to use the funding to strategically expand its team, scale geographically, and pursue new development efforts. Cyted is committed to making early cancer detection accessible to everyone, ensuring that patients at risk of cancer get the care they deserve. Lucy Edwardes Jones from BGF commented: “Cyted is one of the most innovative companies at the intersection of diagnostics and cancer. The company is addressing a real-world issue with a simple and scalable solution. Their technology is already being used across the UK health system with the potential to have a significant impact on patients around the world.” Anthony Aiudi from Morningside added: "We are excited to continue our commitment to Cyted’s fight against upper gastrointestinal cancers. Cyted’s technology will revolutionise the way we detect and monitor the earliest stages of disease. The proven clinical adoption and traction over recent years demonstrate an exciting opportunity for early cancer diagnostics and targeted screening." Cyted will be part of the Start-up Zone at Med-Tech Innovation Expo on 7-8 June 2023 at the NEC, Birmingham on Stand C32F. To register for FREE, visit www.med-techexpo.com